Atlas Trials

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

Clinical trial NCT02034474 · COMPLETED

Trial details

NCT number
NCT02034474
Sponsor
New York State Psychiatric Institute
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
SchizophreniaSchizoaffective Disorder
Start date
2014-02-01
Primary completion
2017-02-06
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.